Results 101 to 110 of about 4,367 (184)

Outcomes of risankizumab use in adults with Crohn's disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study. [PDF]

BMJ Open Gastroenterol
Butler TD, Beard A, Ososanya A, Parr E, Kwok J, Fekadu H, Chater F, Kakosa V, Morgan J, Bonnar C, Kemp K, Nixon E, Kneebone A, Kuriakose Kuzhiyanjal A, Ormerod C, Knight PP, Shuttleworth E, Butcher R, Chatten K, Crooks B, Limdi JK, White K.   +21 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn's Disease: A Real-World Retrospective Cohort Study from Taiwan. [PDF]

J Inflamm Res
Meng MJ, Lin SH, Chen CM, Chen TD, Kuo CJ, Kou T, Chiu CT, Le PH.   +7 more
europepmc   +1 more source

Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry. [PDF]

Inflamm Bowel Dis
Verleye LMM, Pierik MJ, de Vries AC, van Schaik FDM, van der Meulen-de Jong AE, van Dop WA, Löwenberg M, Visschedijk MC, Naber MR, Bouwknegt DG, Römkens TEH, Bodelier AGL, Voorneveld PW, Oldenburg B, Derikx LAAP, Duijvestein M, Mujagić Z, Dutch Initiative on Crohn and Colitis (ICC) .   +17 more
europepmc   +1 more source

Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque Psoriasis. [PDF]

Cureus
Daily A, Danchulis L, Krulikowski K, Shectman B, Riskin SI.   +4 more
europepmc   +1 more source

Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study. [PDF]

Crohns Colitis 360
Sawaf B, Battistin U, Abu-Rumaileh M, Gerges KM, Hallak Y, Abbarh S, Batikh E, Hadaki N, Elhadi M, Regueiro M, Al-Haddad M.   +10 more
europepmc   +1 more source

Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring. [PDF]

Aliment Pharmacol Ther
Ernest-Suárez K, Hoentjen F.
europepmc   +1 more source

Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring. Authors' Reply. [PDF]

Aliment Pharmacol Ther
Ferreiro-Iglesias R, Zabana Y, Barreiro-de Acosta M.   +2 more
europepmc   +1 more source

Efficacy and safety of risankizumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis. [PDF]

Ther Adv Gastroenterol
Nasim H, Siddiqui AH, Khan SJ, Fatima K, Naz A, Yousafzai ZA, Malik J, Naeem N, Khan U, Mahato RK.   +9 more
europepmc   +1 more source

Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report. [PDF]

CEN Case Rep
Yagasaki M, Yamada K, Koshida T, Takagi M, Saeki H, Ogiwara K, Kobayashi T, Kihara M, Gohda T, Suzuki Y.   +9 more
europepmc   +1 more source

Efficacy and safety of risankizumab in moderate to severe psoriasis: an updated systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Shuja H, Farhan K, Wamiq U, Khan MS, Tariq MB, Shakir S, Uzair M, Salomon I.   +7 more
europepmc   +1 more source